Drug pricing reform in the U.S. is both further along than it’s been in years and stuck facing the same long odds that have frustrated past attempts at a major federal overhaul. If recent actions from Congress and the White House are any indication, pricing looks set to remain pharma’s greatest reputational risk of 2022 and beyond.
INCLUDED IN THIS TRENDLINE
Pharma under the microscope as FTC considers new ways to review acquisitions
Drug price hikes moderate as rebates rise, report finds
Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug
Yes, I'd like to sign up for the BioPharma Dive newsletter. You can unsubscribe at any time.By completing this form, you accept the Terms of Use and Privacy Policy. You also agree to having your information shared with our sponsor, AmerisourceBergen.
Please fill in form details to move ahead.
